Lastan

Losartan Potassium, the active ingredient in Lastan, is an angiotensin II receptor blocker presented as a tablet for oral use. It lowers elevated blood pressure and helps protect the heart and kidneys in adult patients with hypertension, heart failure, or diabetic kidney disease.

GNH USA supplies Lastan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Lastan (losartan) acts on the renin‑angiotensin‑aldosterone system to manage several cardiovascular and renal conditions.

Hypertension: reduces systolic and diastolic blood pressure, decreasing risk of stroke and myocardial infarction. Heart failure: improves symptoms, reduces hospitalisation, and prolongs survival in patients with reduced ejection fraction. Diabetic nephropathy: slows progression of kidney damage and lowers proteinuria in patients with type 2 diabetes. Stroke risk reduction: lowers incidence of recurrent stroke in high‑risk hypertensive individuals.

Like all medicines, Losartan may cause unwanted reactions; they are classified by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Back pain - Cough

Serious or Rare Side Effects: - Angioedema - Hyperkalemia - Acute renal failure - Severe hypotension - Hepatic injury - Neutropenia

When prescribing or dispensing Losartan, consider the following precautions to ensure safe use.

Monitor blood pressure: check regularly to avoid hypotension. Assess renal function: evaluate serum creatinine before and during therapy. Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. Use caution in severe hepatic impairment: dose adjustment may be required. Avoid use in pregnancy unless clearly needed: limited data on safety. Store at below 25°C: keep in the original pack, protect from moisture.

Losartan can interact with other medicines; some combinations should be avoided while others need careful monitoring.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Combination with ACE inhibitors or other ARBs: may cause excessive potassium rise and kidney injury. - Use with potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Co‑administration with thiazide diuretics: may enhance hypotensive effect. - Rifampin therapy: may reduce losartan plasma concentrations. - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase losartan levels. - Antacids containing aluminium or magnesium: may decrease absorption if taken simultaneously.